Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Blocking Interfering Microbes: Irinotecan is a widely used anticancer pro-drug that is converted in the liver into the active form, but when it gets into the gut, the normally benign microbial flora can convert it into the toxic form, which kills the rapidly multiplying gut epithelium as it would kill rapidly dividing tumor cells, and thus causes diarrhea. Wallace et al. (p. 831 ; see the Perspective by Patel and Kaufmann ) used high-throughput screening to identify inhibitors that target the offending bacterial enzyme, β-glucuronidase, without killing the bacteria or affecting orthologous mammalian enzymes. Crystal structures revealed the molecular basis of selectivity, and in vivo studies showed that an inhibitor protected mice from irinotecan-induced toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“Toxic or adverse consequences can also ensue, as is the case for irinotecan (Wallace et al., 2010)”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
In the citing paper
“Notably, β-glucuronidase inhibitors are capable of rescuing mice from drug toxicity.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“This specificity towards the bacterial enzymes was revealed with the assistance of crystallography and bioinformatics, which demonstrated that these inhibitors interacted with a “bacterial loop” that is highly conserved and well distributed across the gut bacteria enzymes, but is absent from the mammalian enzyme146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“The answer appears to be yes for the bacterial β-glucuronidases, for which multiple inhibitors now exist that have minimal impact on the mammalian homolog143–146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
CDD: specific functional annotation with the Conserved Domain Database
Marchler-Bauer, A., Anderson, J. B., Chitsaz, F., Derbyshire, M. K., DeWeese-Scott, C., Fong, J. H., Geer, L. Y., Geer, R. C., Gonzales, N. R., Gwadz, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn845 · Cited by 1,071
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Three-dimensional structure of β-galactosidase from E. coli.
Jacobson, R. H., Zhang, X.-J., DuBose, R. F., & Matthews, B. W. (1994) · Nature · doi:10.1038/369761a0 · Cited by 600
Cummings, J. H., & Macfarlane, G. T. (1997) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607197021006357 · Cited by 437
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Stein, A., Voigt, W., & Jordan, K. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009355164 · Cited by 431
A dynamic partnership: Celebrating our gut flora
Sears, C. L. (2005) · Anaerobe · doi:10.1016/j.anaerobe.2005.05.001 · Cited by 414
Pizzolato, J. F., & Saltz, L. B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13780-4 · Cited by 359
Role of intestinal bacteria in nutrient metabolism
Cummings, J. H., & Macfarlane, G. T. (1997) · Clinical Nutrition · doi:10.1016/s0261-5614(97)80252-x · Cited by 277
Structure of human β-glucuronidase reveals candidate lysosomal targeting and active-site motifs
Jain, S., Drendel, W. B., Chen, Z.-W., Mathews, F. S., Sly, W. S., & Grubb, J. H. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0496-375 · Cited by 216
Pharmacogenetics of irinotecan metabolism and transport: An update
Smith, N. F., Figg, W. D., & Sparreboom, A. (2006) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.045 · Cited by 190
Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections
Nord, C. E., Kager, L., & Heimdahl, A. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90250-x · Cited by 164
Adenosine Kinase Inhibitor GP515 Improves Experimental Colitis in Mice
Siegmund, B., Rieder, F., Albrich, S., Wolf, K., Bidlingmaier, C., Firestein, G. S., Boyle, D., Lehr, H.-A., Loher, F., Hartmann, G., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29668-3 · Cited by 128
Lessons Learned from the Irinotecan Metabolic Pathway
Ma, M., & McLeod, H. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368619 · Cited by 122
Nagar, S., & Blanchard, R. L. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600739835 · Cited by 116
Bacteria, inflammation, and colon cancer
Yang, L. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i42.6741 · Cited by 82
Bifidobacteria and probiotic effects: Action of Bifidobacterium species on conjugated bile salts
Grill, J.-P., Manginot-D�rr, C., Schneider, F., & Ballongue, J. (1995) · Current Microbiology · doi:10.1007/bf00294629 · Cited by 82
Identification and Cloning of gusA , Encoding a New β-Glucuronidase from Lactobacillus gasseri ADH
Russell, W. M., & Klaenhammer, T. R. (2001) · Applied and Environmental Microbiology · doi:10.1128/aem.67.3.1253-1261.2001 · Cited by 73
Structural insights into the function of type IB topoisomerases
Redinbo, M. R., Champoux, J. J., & Hol, W. G. J. (1999) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(99)80005-0 · Cited by 70
Self-citationKurita, A., Kado, S., Matsumoto, T., Asakawa, N., Kaneda, N., Kato, I., Uchida, K., Onoue, M., & Yokokura, T. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1310-4 · Cited by 66
Hu, Z., Yang, X.-X., Chan, S. Y., Xu, A.-L., Duan, W., Zhu, Y. Z., Sheu, F., Boelsterli, U. A., Chan, E., Zhang, Q., et al. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.05.020 · Cited by 64
Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats
Fittkau, M., Voigt, W., Holzhausen, H.-J., & Schmoll, H. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0557-8 · Cited by 52
Flieger, D., Klassert, C., Hainke, S., Keller, R., Kleinschmidt, R., & Fischbach, W. (2007) · Oncology · doi:10.1159/000111083 · Cited by 45
Review article: antibiotic‐induced Clostridium difficile infection
SETTLE, C. D., & WILCOX, M. H. (1996) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1996.79251000.x · Cited by 38
Farnleitner, A. H., Hocke, L., Beiwl, C., Kavka, G. G., & Mach, R. L. (2002) · Water Research · doi:10.1016/s0043-1354(01)00288-3 · Cited by 36
A New Potent β-Glucuronidase Inhibitor, D-Glucaro-δ-lactam Derived from Nojirimycin
NIWA, T., Tsuruoka, T., Inouye, S., NAITO, Y., KOEDA, T., & NIIDA, T. (1972) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a129889 · Cited by 34
Biochemical basis of the beta-glucuronidase gene defect causing canine mucopolysaccharidosis VII
Ray, J., Scarpino, V., Laing, C., & Haskins, M. E. (1999) · Journal of Heredity · doi:10.1093/jhered/90.1.119 · Cited by 22
Beta-glucuronidase in physiology and disease.
Basińska-Ziobroń, A., & Floriańczyk, B. (2003) · PubMed · Cited by 18
Kurita, H., Yamamoto, E., Nozaki, S., Wada, S., Furuta, I., Miyata, M., & Kurashina, K. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1056-z · Cited by 17
Tobin, P., Dodds, H., Clarke, S., Schnitzler, M., & Rivory, L. (2003) · Oncology Reports · doi:10.3892/or.10.6.1977 · Cited by 17
Sears, S., McNally, P. R., Bachinski, M. S. Z., & Avery, R. (1999) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(99)70171-9 · Cited by 16
Stamp, D. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.05.005 · Cited by 6
(1981) · PubMed
Research works printed but not linked: 4
- Mathijssen RHJ Clin Cancer Res 7 2182 2001 11489791
- Basińska A Floriańczyk B Ann Univ Mariae Curie Sklodowska Med 58 386 2003 15323223
- Jain S Nat Struct Mol Biol 3 375 1996 · DOI · Paper page
- Brattain MG Fine WD Khaled FM Thompson J Brattain DE Cancer Res 41 1751 1981 7214343
Cited by
Role of the normal gut microbiota
Jandhyala, S. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i29.8787 · Cited by 3,001
The gut microbiota, bacterial metabolites and colorectal cancer
Louis, P., Hold, G. L., & Flint, H. J. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3344 · Cited by 2,816
Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817
“Earlier studies on the association between bacteria and cancer have focused primarily on exploring (i) the role of bacteria in tumor pathogenesis, (ii) the potential of gut bacteria to modulate anti-tumor immune responses (18, 19), and (iii) the contribution of bacterial metabolism to the adverse effects of chemothera…”
BackgroundSchwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
Self-citationGarrett, W. S. (2015) · Science · doi:10.1126/science.aaa4972 · Cited by 1,404
Metadata
- Authors
- Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., & Redinbo, M. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Albert Einstein College of Medicine (US)
- North Carolina Central University (US)
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 831-835
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3110694
- OpenAlex
- W2140145798
- Cited by
- 1,080
- References
- 39
- Citations by year
- 2026: 97 · 2025: 80 · 2024: 103 · 2023: 101 · 2022: 92 · 2021: 92 · 2020: 100 · 2019: 82 · 2018: 70 · 2017: 67 · 2016: 47 · 2015: 33 · 2014: 34 · 2013: 28 · 2012: 29
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Damon Runyon Cancer Research Foundation
- Golden LEAF Foundation
- National Institutes of Health
- National Cancer Institute (CA 127231, R01CA161879, R01CA127231, CA98468, R01CA098468)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073338)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, chemotherapy-induced diarrhea, enzyme inhibitors, gut microbiota, commensal bacteria, substrate specificity, crystal structure, high-throughput screening, oral administration, colon cancer, drug toxicity
- MeSH terms
- Irinotecan, Animals, Antineoplastic Agents, Phytogenic, Bacteria, Anaerobic, Camptothecin, Colon, Diarrhea, Drug Evaluation, Preclinical, Enzyme Inhibitors, Escherichia coli, Female, Glucuronidase, Humans, Intestinal Mucosa, Mice, Inbred BALB C, Models, Molecular, Prodrugs, Protein Conformation, Crystallography, X-Ray, Escherichia coli Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.